Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel

References

• Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:S79-88
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP Intensive statin therapy for treating acute coronary syndromes. Exp Opin Investig Drugs 2006;15:1151-9
   PubMed Web of Science ®Google Scholar
• Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998;352:507-14
   PubMed Web of Science ®Google Scholar
• Cronin S, Yusuf M, Flather M, et al. OASIS registry 2-year follow-up: outcomes in patients with unstable angina or myocardial infarction without ST segment elevation admitted to hospitals with or without catheterization facilities [abstract]. Eur Heart J 2000;21:247
   Web of Science ®Google Scholar
• Cohen M, Stinnett SS, Weatherley BD, et al. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000;139:962-70
   PubMed Web of Science ®Google Scholar
• McCollam PI, Etemad LR Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-6
   PubMedGoogle Scholar
• McCollam P, Etemad L. Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization. J Invasive Cardiol 2005;17:307-11
   PubMedGoogle Scholar
• Cannon CP; CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002;90:760-2
   PubMed Web of Science ®Google Scholar
• Fox KA, Mehta SR, Peters R, et al. Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction. J Am Coll Cardiol 2007;50:e1-157
   Google Scholar
• Juergens CP, Wong AM, Leung DY, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation. Am Heart J 2004;147:E15
   PubMed Web of Science ®Google Scholar
• Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006;18:162-4
   PubMedGoogle Scholar
• Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 3 September 2009]
   Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2008. Available from: http://data.bls.gov/cgi-bin/surveymost?su [last accessed: 11 September 2009]
   Google Scholar
• Lin DY Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47
   PubMedGoogle Scholar
• Carides G, Heyse J, Iglewics B. A regression-based method for estimating mean treatment cost in the presence of right censoring. Biostatistics 2000;1:299-313
   PubMedGoogle Scholar
• Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007;49:734-9
   PubMed Web of Science ®Google Scholar
• Weintraub W, Jonsson B, Bertrand M. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomics 2004;22:29-41
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Mahoney EM, Lamy A et al. CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838-45
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006;24:709-26
   PubMed Web of Science ®Google Scholar
• Schleinitz MD, Heidenreich PA A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9
   PubMed Web of Science ®Google Scholar
• Cheng JW Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. J Manag Care Pharm 2007;13:326-36
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. Circulation 2006;113:1683-92
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006;113:1693-701
   PubMed Web of Science ®Google Scholar